Duygu ERYAVUZ ONMAZ, Canan AYDOĞAN, Nazif AYGÜL, Abdullah SİVRİKAYA, Sedat ABUŞOĞLU, Ali ÜNLÜ

Periferik arter hastalarinda yükselmiş serum homositrulin düzeyleri

Amaç: Periferik arter hastalığı (PAH) arteriyel stenoz veya oklüzyon ile karakterize, kronik, progresif bir hastalıktır. Ateroskleroz PAH’ın en yaygın nedenidir (>%90). Karbamilasyon, proteinlerin post translasyonel modifikasyon mekanizmalarından birisi olup ateroskleroz için yeni bir risk faktörü olarak tanımlanmıştır. Bilinen en yaygın karbamilasyon ürünü ise homositrulindir. Bu çalışmamızda PAH’lı hastalar ile benzer yaş, cinsiyet dağılımı ve risk faktörlerine sahip PAH’ı olmayan bireylerde serum homositrulin düzeylerini ölçerek homositrulinin PAH tanısındaki rolünün aydınlatılmasına katkıda bulunmak ve çeşitli biyolojik parametreler ile homositrulin düzeyleri arasındaki ilişkiyi araştırmak amaçlanmıştır. Yöntem: Çalışmaya, 70 PAH’lı hasta ve 65 PAH’ı olmayan birey dahil edilmiştir. Serum homositrulin ve lizin düzeyleri AB Sciex API 3200 (Applied Biosystems/MDS Sciex) likit kromatografi-tandem kütle spektrometri (LC- MS/MS) cihazıyla geliştirmiş olduğumuz geçerli kılınmış yöntemle ölçülmüştür. Hastalara ait çeşitli hematolojik ve biyokimyasal parametreler sırasıyla Beckman Coulter LH 780 ve Beckman Coulter AU 5800 (Beckman Coulter,Brea, USA) otoanalizörlerinde, C-reaktif protein (CRP) düzeyleri ise IMMAGE 800 (Beckman Coulter, Brea, USA) cihazında ölçülmüştür. Bulgular: PAH’lı hastaların serum homositrulin konsantrasyonları kontrol grubuna göre istatiksel olarak anlamlı düzeyde yüksekti (p

Elevated serum homocitrulline levels in patients with peripheral artery disease

Objective: Peripheral arterial disease (PAH) is a chronic, progressive disease characterized by arterial stenosis or occlusion. Atherosclerosis is the most common cause of PAH (>90%). Carbamylation is one of the post-translational modification mechanisms of proteins and has been identified as a new risk factor for atherosclerosis. The most common carbamylation product known is homocitrulline. Our aim in this study was to contribute to the elucidation of the role of homocitrulline in the diagnosis of PAH. Methods: 70 patients with PAH and 65 individuals without PAH were included in the study. Serum homocitrulline and lysine levels were measured by AB Sciex API 3200 (Applied Biosystems/MDS Sciex) liquid chromatography-tandem mass spectrometry (LC-MS/ MS) device. Various hematological and biochemical parameters of the patients were measured in Beckman Coulter LH 780 and Beckman Coulter AU 5800 (Beckman Coulter, Brea, USA) autoanalyzers, and C-reactive protein (CRP) levels were measured in IMMAGE 800 (Beckman Coulter, Brea, USA) device, respectively. Results: Serum homocitrulline concentrations of patients with PAH were statistically significantly higher than the control group (p

PDF

___

1. Shu J, Santulli G. Update on peripheral artery disease: Epidemiology and evidence-based facts. Atherosclerosis, 2018; 275:379-81.
2. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res, 2015; 116(9):1509-26.
3. Solomon C, Kullo I, Rooke T. Peripheral artery disease. N Engl J Med, 2016; 374:861-71.
4. Signorelli SS, Marino E, Scuto S, Di Raimondo D. Pathophysiology of peripheral arterial disease (PAD): a review on oxidative disorders. Int J Mol Sci, 2020; 21(12).
5. Eid MA, Mehta KS, Goodney PP. Epidemiology of peripheral artery disease. Semin Vasc Surg, 2021; 34(1):38-46.
6. Soyoye DO, Abiodun OO, Ikem RT, Kolawole BA, Akintomide AO. Diabetes and peripheral artery disease: A review. World J Diabetes, 2021; 12(6):827-38.
7. Serra R, Abramo A, Ielapi N, Procopio S, Marino P. Environmental pollution and peripheral artery disease. Risk Manag Healthc Policy, 2021; 14:2181- 90.
8. Kim C, Yang YS, Ryu GW, Choi M. Risk factors associated with amputation-free survival for patients with peripheral arterial disease: a systematic review. Eur J Cardiovasc Nurs, 2021; 20(4):295-304.
9. Verbrugge FH, Tang WHW, Hazen SL. Protein carbamylation and cardiovascular disease. Kidney Int, 2015; 88(3):474-8.
10. Shi J, van Veelen PA, Mahler M, Janssen GM, Drijfhout JW, Huizinga TW, et al. Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev, 2014; 13(3):225-30.
11. Delanghe S, Delanghe JR, Speeckaert R, Van Biesen W, Speeckaert MM. Mechanisms and consequences of carbamoylation. Nat Rev Nephrol, 2017; 13(9):580-93.
12. Delanghe S, Delanghe JR, Speeckaert R, Van Biesen W, Speeckaert MM. Mechanisms and consequences of carbamoylation. Nat Rev Nephrol, 2017; 13(9):580-93.
13. Teng N, Maghzal GJ, Talib J, Rashid I, Lau AK, Stocker R. The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture. Redox Rep, 2017; 22(2):51-73.
14. Jaisson S, Desmons A, Doué M, Gorisse L, Pietrement C, Gillery P. Measurement of homocitrulline, a carbamylation-derived product, in serum and tissues by LC-MS/MS. Curr Protoc Protein Sci, 2018; 92.
15. Dietzen DJ, Weindel AL, Carayannopoulos MO, Landt M, Normansell ET, Reimschisel TE, et al. Rapid comprehensive amino acid analysis by liquid chromatography/tandem mass spectrometry: comparison to cation exchange with post- column ninhydrin detection. Rapid Commun Mass Spectrom, 2008; 22(22):3481-8.
16. Chen L, Kashina A. Post-translational modifications of the protein termini. Front Cell Dev Biol, 2021; 9:719590.
17. Ramazi S, Zahiri J. Post-translational modifications in proteins: resources, tools and prediction methods. Database, 2021; 2021:1-20.
18. Zhang H, Han W. Protein post-translational modifications in head and neck cancer. Front Oncol, 2020; 10(2124).
19. Chatterjee B, Thakur SS. Investigation of post- translational modifications in type 2 diabetes. Clin Proteomics, 2018; 15(32):1-11.
20. Gupta R, Sahu M, Srivastava D, Tiwari S, Ambasta RK, Kumar P. Post-translational modifications: Regulators of neurodegenerative proteinopathies. Ageing Res Rev, 2021; 68:101336.
21. Marquez J, Lee SR, Kim N, Han J. Post-translational modifications of cardiac mitochondrial proteins in cardiovascular disease: not lost in translation. Korean Circ J, 2016; 46(1):1-12.
22. Gao S, Zhao D, Wang M, Zhao F, Han X, Qi Y, et al. Association between circulating oxidized LDL and atherosclerotic cardiovascular disease: a meta- analysis of observational studies. Can J Cardiol, 2017; 33(12):1624-32.
23. Zimmermann R, Panzenböck U, Wintersperger A, Levak-Frank S, Graier W, Glatter O, et al. Lipoprotein Lipase Mediates the Uptake of Glycated LDL in Fibroblasts, Endothelial Cells, and Macrophages. Diabetes, 2001; 50(7):1643-53.
24. Poznyak AV, Nikiforov NG, Markin AM, Kashirskikh DA, Myasoedova VA, Gerasimova EV, et al. Overview of OxLDL and its impact on cardiovascular health: focus on atherosclerosis. Front Pharmacol, 2020; 11:613780.
25. de Vos LC, Lefrandt JD, Dullaart RP, Zeebregts CJ, Smit AJ. Advanced glycation end products: An emerging biomarker for adverse outcome in patients with peripheral artery disease. Atherosclerosis, 2016; 254:291-9.
26. Gorisse L, Pietrement C, Vuiblet V, Schmelzer C, Köhler M, Duca L, et al. Protein carbamylation is a hallmark of aging. Proc Natl Acad Sci, 2015; 113:201517096.
27. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Hörkkö S, Barnard J, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med, 2007; 13(10):1176-84.
28. Tang WHW, Shrestha K, Wang Z, Borowski AG, Troughton RW, Klein AL, et al. Protein carbamylation in chronic systolic heart failure: relationship with renal impairment and adverse long-term outcomes. J Card Fail, 2013; 19(4):219- 24.
29. Jaisson S, Kerkeni M, Santos-Weiss IC, Addad F, Hammami M, Gillery P. Increased serum homocitrulline concentrations are associated with the severity of coronary artery disease. Clin Chem Lab Med, 2015; 53(1):103-10.
30. Ramachandra CJA, Ja KPMM, Chua J, Cong S, Shim W, Hausenloy DJ. Myeloperoxidase as a multifaceted target for cardiovascular protection. antioxidants & redox signaling, 2019; 32(15):1135- 49.
31. Kimak E, Zięba B, Duma D, Solski J. Myeloperoxidase level and inflammatory markers and lipid and lipoprotein parameters in stable coronary artery disease. Lipids Health Dis. 2018;17(1):71.
32. Roth Flach RJ, Su C, Bollinger E, Cortes C, Robertson AW, Opsahl AC, et al. Myeloperoxidase inhibition in mice alters atherosclerotic lesion composition. PLoS One, 2019; 14(3):e0214150.
33. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol, 2005; 25(6):1102-11.
34. Chen Z, Ding S, Wang YP, Chen L, Mao JY, Yang Y, et al. Association of carbamylated high-density lipoprotein with coronary artery disease in type 2 diabetes mellitus: carbamylated high-density lipoprotein of patients promotes monocyte adhesion. J Transl Med, 2020; 18(1):460.